Navigation Links
Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
Date:8/21/2008


Satisfies initial listing requirements with NASDAQ; Stock Symbol 'OGXI'

Implements immediate restructuring program, which extends cash runway

while focusing on clinical pipeline programs

BOTHELL, WA, Aug. 21 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (formerly Sonus Pharmaceuticals, Inc.) (NASDAQ: OGXI) (the "Company") announced that the Company has completed its acquisition of OncoGenex Technologies and NASDAQ has approved the commencement of trading in Company's common stock on The NASDAQ Capital Market under the stock symbol 'OGXI' effective today, August 21, 2008, when the market opens. Prior to completing the acquisition, the Company changed its name to OncoGenex Pharmaceuticals, amended its authorized share capital and effected a one-for-eighteen reverse stock split.

"Clearly the shareholders of both companies, Sonus Pharmaceuticals and OncoGenex Technologies, strongly favored this transaction and our efforts to maintain a NASDAQ listing," said Scott Cormack, President and Chief Executive Officer of OncoGenex Pharmaceuticals. "On August 19th, a very strong percentage of Sonus' shareholders voted in favor of the transaction and voted in favor of a reverse stock split. One hundred percent of OncoGenex Technologies' shareholders voted in favor of the transaction."

Additionally, as announced on August 20th, the Company has implemented cost-saving measures to preserve cash while focusing on its highest potential product development programs. The Company will reduce workforce by approximately 49%. As a result of these actions, the Company will incur approximately $1.2 million in charges in the third quarter of 2008, associated with employee severance costs. Management estimates that
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
2. Sonus Pharmaceuticals Receives Favorable NASDAQ Decision
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
7. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
8. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
9. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
10. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
11. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... Virginia , September 2, 2015 ... der Gewinner des Wettbewerbs BeHEARD von 2015 bekanntgeben ... internationalen vom Rare Genomics Institute. Biovista ... von Medikamenten für die Behandlung anderer Krankheiten als ... Steven Laffoon und sein Team bei ...
(Date:9/2/2015)... ... 2015 , ... Whitehouse Laboratories is excited to announce that ... upcoming educational seminar and training session on Extractable & Leachable testing. Featuring a ... Updates & Case Studies on the Latest Compliance Implications of USP and ICH ...
(Date:9/2/2015)... ... September 02, 2015 , ... The ... creating professional commercial video content, to analysis of athletic performance. Producing high-resolution ... go by too quickly to process with the naked eye. , Slow ...
(Date:9/1/2015)... , September 2, 2015 ... primär auf die Forschung und Entwicklung neuartiger ... Allergien, chronisch-entzündliche Darmerkrankungen und Reizdarm konzentriert, erhält ... Zusage, dass sein neues Medikament patentiert wird. ... das Allergien bei Kindern verhindert und Entzündungen ...
Breaking Biology Technology:Biovista sponsert die Forschung von Wylder Nation Foundation zum Thema Mangel an saurer Sphingomyelinase 2Whitehouse Laboratories to Participate in Pharm Ed Resources Extractables, Leachables, & Elemental Impurities Educational Seminar 2Whitehouse Laboratories to Participate in Pharm Ed Resources Extractables, Leachables, & Elemental Impurities Educational Seminar 3Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 2Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 3Das Patent von Swecure zur Verhinderung von Allergien bei Kindern wird in den USA zugelassen 2
... PALO ALTO, Calif. , May 4 "BIO has ... of the biotechnology sector.  It is my goal to build upon these ... fosters the right policy environment for the biobased solutions that our industry ... , , ...
... GENEVA, SWITZERLAND , May 4 /PRNewswire-FirstCall/ - Anavex Life ... from animal studies with ANAVEX 2-73, the company,s lead compound for ... , , ... a new class of drugs that target mitochondrial dysfunction thought to ...
... which have four triangular sides, pack more densely than ... by a collaboration of New York University and Virginia ... series of experiments that involved pouring tetrahedral dice into ... containers were completely filled. After adding water to measure ...
Cached Biology Technology:Statement from Genencor CEO Tjerk de Ruiter Upon Being Elected as Chair of the Industrial & Environmental Section and Board of Directors of the Biotechnology Industry Association (BIO) 2Anavex reports animal study results as lead Alzheimer's compound approaches phase 1 clinical trials 2Anavex reports animal study results as lead Alzheimer's compound approaches phase 1 clinical trials 3Anavex reports animal study results as lead Alzheimer's compound approaches phase 1 clinical trials 4Anavex reports animal study results as lead Alzheimer's compound approaches phase 1 clinical trials 5Densest dice packing and computing with molecules 2
(Date:8/19/2015)... Aug. 19, 2015  VOXX International Corporation (Nasdaq: ... entered into a Definitive Agreement to purchase the ... authentication market leader EyeLock through an acquiring entity.  ... a controlling interest in the acquiring entity. The ... of due diligence.  Expanding on its existing supply ...
(Date:8/18/2015)... , Aug. 17, 2015 Research and ... of the "Global Biometric Authentication & Identification ... Estimation & Forecast, 2015-2020" report to their ... and identification systems market is expected to grow ... to 2020 and generate over $25 billion (approximately) ...
(Date:8/12/2015)... 2015   MedNet Solutions , an innovative SaaS-based ... clinical research, is proud to announce that ... eClinical technology platform, has led the way to significant ... of 2015.   Q2 2015 and Q1 2015 were, ... contract value sold in the company,s 15 year history.  ...
Breaking Biology News(10 mins):VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5Global Biometric Authentication & Identification Market 2015: Focus On Modality, Motility & Application - Estimation & Forecasts to 2020 for the $25 Billion Industry 2MedNet Solutions Experiences Explosive Corporate Growth 2
... in 1971 and have become a leading international forum ... and biocatalysis, putting an emphasis on emerging technologies and ... The proposed scope and thrust of the conference will ... developments in fields including protein design and computation, catalytic ...
... - Adrenaline, the hormone that prepares our body to ... molecule switches so fast between several positions, that it ... Jan Steyaert of VIB and the Vrije Universiteit Brussel ... US, have "frozen the molecule in action" using Xaperones, ...
... In the late 1950s, Richard Feynman famously imagined a ... by manipulating matter and creating structures all the way ... over fifty years after "There,s Plenty of Room at ... Angela Belcher, Donald Eigler, and Michael Roukes - are ...
Cached Biology News:Adrenaline receptor 'frozen in action' by VIB researchers 2Scaling up: The future of nanoscience 2Scaling up: The future of nanoscience 3
Any form, any size, any number of mutageneses. ExonBio provides the best service with double sequecing to make sure the success of the mutagenesis....
Loading Buffer...
Request Info...
Request Info...
Biology Products: